Get all your news in one place.
100's of premium titles.
One app.
Start reading
Medical Daily
Medical Daily
Health
Elena Vega

UNBELIEVABLE: Gileads experimental ulcerative colitis pill beat placebo by 23 points on remission but long term safety data are pending - The Untold Story

An experimental once-daily pill from Gilead Sciences helped more people with moderate to severe ulcerative colitis reach remission than a placebo in a mid-stage trial, the company reported on October 19. After 12 weeks, 31% of patients taking the highest dose were in clinical remission, compared with 8% of those on placebo, a gap of 23 percentage points.

The results come from the Phase 2 SWIFT study and were presented as a late-breaking abstract at United European Gastroenterology Week in Barcelona. The drug, called emvistegrast, is not approved anywhere, and the longer-term safety and maintenance data needed to judge it fully are still being collected.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.